Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis. (July 2022)

• Record Type: Journal Article
• Authors: Yamani, Naser; Unzek, Samuel; Mankani, Muhammad Hasnain; Almas, Talal; Musheer, Adeena; Qamar, Humera; Farooq, Shausha; Shahnawaz, Waqas; Fatima, Kaneez; Figueredo, Vincent; Mookadam, Farouk
• Is Part Of: Annals of medicine and surgery. Volume 79(2022)
• Publication Date: 2022-07
• Subjects: Antiplatelet -- Percutaneous -- Mortality -- Cardiovascular; Surgery -- Periodicals; Medicine -- Periodicals; General Surgery -- Periodicals; Education, Medical -- Periodicals; Periodicals; 617
• DOI: 10.1016/j.amsu.2022.103964
• Languages: English
• ISSNs: 2049-0801

Abstract

Abstract: Background: The potential benefits of individualized guided selection of antiplatelet therapy over standard antiplatelet therapy in improving outcomes in patients undergoing percutaneous coronary intervention (PCI) have not been established. Therefore, we pooled evidence from available clinical trials to assess the effectiveness by comparing the two regimens in patients undergoing PCI. Methods: We queried two electronic databases, MEDLINE and Cochrane CENTRAL, from their inception to April 20, 2021 for published randomized controlled trials in any language that compared guided antiplatelet therapy, using either genetic testing or platelet function testing, versus standard antiplatelet therapy in patients undergoing PCI. The results from trials were presented as risk ratios (RRs) with 95% confidence intervals (CIs) and were pooled using a random-effects model. Results: Eleven eligible studies consisting of 18, 465 patients undergoing PCI were included. Pooled results indicated that guided antiplatelet therapy, compared to standard therapy, was associated with a significant reduction in the incidence of MACE [RR 0·78, 95% CI (0·62–0·99), P = 0·04], MI [RR 0·73, 95% CI (0·56–0.96), P = 0·03], ST [RR 0·66, 95% CI (0·47–0.94), P = 0·02], stroke [RR 0·71, 95% CI (0·50–1.00), P = 0·05], and minor bleeding [RR 0·78, 95% CI (0·66–0.91), P = 0·003]. Conclusions: Individualized guided selection of antiplatelet therapy significantly reduced the incidence of MACE, MI, ST, stroke, and minor bleeding in adult patients when compared with standard antiplatelet therapy. Our findings support the implementation of genetic and platelet function testing to select the most beneficial antiplatelet agent. Highlights: Benefits of individualized guided selection of antiplatelet therapy over standard antiplatelet therapy in improving outcomes in patients undergoing percutaneous coronary intervention (PCI) have not been established. Guided therapy, consisting of either genetic testing or platelet function testing, can identify patients with this genetic variation allowing clinicians to provide modified and alternative treatment strategies and prescribe optimal antiplatelet agents. Individualized guided selection of antiplatelet therapy reduced the incidence of MACE, MI, ST, stroke, and minor bleeding in adult patients when compared with standard antiplatelet therapy. Can be more cost-effective than medication cost for every stroke, in-stent thrombosis, or MI case that needs hospitalization requiring more imaging and tests which can increase the total cost of treatment.